重新定义多发性骨髓瘤治疗:免疫疗法的进展,挑战和未来方向
Chengcheng Fu1,2, Yingying Zhai1,2, Lingzhi Yan1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China.
多发性骨髓瘤 (MM) 的治疗方法正在发展,免疫疗法对复发性或耐药性疾病显示出希望. 实现最小的残留疾病负面影响对于更好的患者结果至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 多发性骨髓瘤 (MM) 是一种复杂的血液性恶性瘤,其特点是异质性,复发性和耐治疗性.
- 尽管取得了进展,MM仍然在很大程度上无法治愈,需要新的治疗策略.
- 传统的治疗方法面临着局限性,需要更有效的方法.
研究的目的:
- 审查当前多发性骨髓瘤的治疗环境.
- 强调传统疗法的局限性和免疫疗法的日益重要.
- 突出新兴的免疫治疗策略,以改善患者的治疗结果.
主要方法:
- 关于多发性骨髓瘤治疗的当前文献的综述.
- 评估传统疗法及其局限性.
- 分析免疫疗法的进展,包括CAR T细胞疗法,双特异性抗体和T细胞参与剂.
主要成果:
- 免疫疗法提供了更好的前景,特别是在复发性或耐火性MM.
- 像CAR T细胞疗法这样的创新策略显示出显著的前景.
- 准恶性细胞和骨髓微环境是克服抗性的关键.
结论:
- 最少的残留疾病负面性和平衡的免疫反应是关键的治疗目标.
- 早期将免疫治疗纳入治疗线和开发预测生物标志物是未来的研究方向.
- 个性化治疗方法对于改善多发性骨髓瘤患者的治疗结果至关重要.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
